Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Virus or bacteriophage
Reexamination Certificate
2003-12-18
2009-02-03
Campell, Bruce (Department: 1648)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Virus or bacteriophage
C424S204100, C424S093700, C435S235100, C536S023720, C514S04400A
Reexamination Certificate
active
07485292
ABSTRACT:
There are provided methods for treatment of abnormal cells such as cancer cells in a mammal. The methods involve treating the mammal with virus selected from echoviruses and modified forms and combination thereof, which recognize α2β1for infectivity of the cells. There are also provided methods for screening viruses for use in a method of the invention as well as pharmaceutical compositions for use in the methods.
REFERENCES:
patent: 5529774 (1996-06-01), Barba et al.
patent: 5585096 (1996-12-01), Martuza et al.
patent: 5585254 (1996-12-01), Maxwell et al.
patent: 5601818 (1997-02-01), Freeman et al.
patent: 5674729 (1997-10-01), Wimmer et al.
patent: 5681731 (1997-10-01), Lebkowski et al.
patent: 5688773 (1997-11-01), Chiocca et al.
patent: 5972706 (1999-10-01), McCormick
patent: 6060316 (2000-05-01), Young et al.
patent: 6110461 (2000-08-01), Lee et al.
patent: 6136307 (2000-10-01), Lee et al.
patent: 6261555 (2001-07-01), Lee et al.
patent: 6264940 (2001-07-01), Gromeier et al.
patent: 1994699487 (1994-11-01), None
patent: 1996699811 (1996-12-01), None
patent: 1998726500 (1998-09-01), None
patent: 2000776401 (2000-09-01), None
patent: 2001782402 (2001-04-01), None
patent: 2001776061 (2001-05-01), None
patent: 2001782020 (2001-05-01), None
patent: 2001770517 (2001-06-01), None
patent: 2001/784776 (2001-10-01), None
patent: 20011268146 (2001-12-01), None
patent: 2003258060 (2003-10-01), None
patent: 2004202292 (2004-06-01), None
patent: 2004203458 (2004-08-01), None
patent: 2005201079 (2005-04-01), None
patent: 2 051 289 (1992-03-01), None
patent: 1032269 (2000-09-01), None
patent: WO 90/12087 (1990-10-01), None
patent: WO 93/09221 (1993-05-01), None
patent: WO 94/18992 (1994-09-01), None
patent: WO 96/00007 (1996-01-01), None
patent: WO 99/18799 (1999-04-01), None
patent: WO 94/18992 (1999-09-01), None
patent: WO 99/45783 (1999-09-01), None
patent: WO 00/08166 (2000-02-01), None
patent: WO 00/62735 (2000-10-01), None
patent: WO 01/04334 (2001-01-01), None
patent: WO 01/12815 (2001-02-01), None
patent: WO 01/19380 (2001-03-01), None
patent: WO 01/53506 (2001-07-01), None
patent: WO 02/43647 (2002-06-01), None
patent: WO 02/50304 (2002-06-01), None
patent: WO 02/087625 (2002-11-01), None
patent: WO 02/091997 (2002-11-01), None
patent: WO 02/092826 (2002-11-01), None
patent: WO 03/008586 (2003-01-01), None
patent: WO 03/010306 (2003-02-01), None
patent: WO 03/073918 (2003-09-01), None
patent: WO 03/082200 (2003-10-01), None
patent: WO 03/092579 (2003-11-01), None
patent: WO 03/094938 (2003-11-01), None
patent: WO 2004/003562 (2004-01-01), None
patent: WO 2004/054613 (2004-07-01), None
patent: WO 2005/002607 (2005-01-01), None
patent: WO 2005/007824 (2005-01-01), None
patent: WO 2005/030139 (2005-04-01), None
patent: WO 2005/087931 (2005-09-01), None
patent: WO 2005/107474 (2005-11-01), None
patent: WO 2006/002394 (2006-01-01), None
patent: WO 2006/047301 (2006-05-01), None
Ferdat et al. Eksp. Onkol. 1989, vol. 11, No. 5, pp. 43-48. Abstract only.
Andreansky, et al., “The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors.”Proc. Natl. Acad. Sci. USAvol. 93, pp. 11313-11318 (1996).
Ansardi, et al., “RNA Replicons Derived from Poliovirus Are Directly Oncolytic for Human Tumor Cells of Diverse Origins.”Cancer Research, vol. 61, pp. 8470-8479 (2001).
Bartolazzi, et al., “Localization of the alpha 3 beta 1 Integrin in Some Common Epithelial Tumors of the Ovary and in Normal Equivalents.”AntiCancer Research,13:1-12 (1993).
Bergelson, et al., “The Integrin VLA-2 Binds Echovirus 1 and Extracellular Matrix Ligands by Different Mechanisms.”J. Clin. Invest.,vol. 92, pp. 232-239 (1993).
Cannistra, et al., “Expression and Function of beta 1 and alpha v beta 3 Integrins in Ovarian Cancer.”Gynecologic Oncology,vol. 58, pp. 216-225 (1995).
Cardarelli, et al., “The Collagen Receptor alpha 2 beta 1, from MG-63 and HT1080 Cells, Interacts with a Cyclic RGD Peptide.”The Journal of Biological Chemistry, vol. 267, No. 32, pp. 23159-23164 (1992).
Casey, et al., “Beta 1-Integrins Regulate the Formation and Adhesion of Ovarian Carcinoma Multicellular Spheriods,”American Journal of Pathology,vol. 159, No. 6, pp. 2071-2080 (2001).
Chan, et al., “In Vitro and in Vivo Consequences of VLA-2 Expression on Rhabdomyosarcoma Cells.” Science, vol. 251, pp. 1600-1602 (1991).
Frankel, et al., “Abrogation of Taxol-induced G2-M Arrest and Apoptosis in Human Ovarian Cancer Cells Grown as Multicellular Tumor Spheriods.”Cancer Research,vol. 57, pp. 2388-2393 (1997).
He, et al., “A simplified system for generating recombinant adenoviruses.”Proc. Natl. Acad. Sci.USA, vol. 95, pp. 2509-2514 (1998).
Kamata, Tetsuji and Takada, Yoshikazu, “Direct Binding of Collagen to the I Domain of Integrin α2β1 (VLA-2, CD49b/CD29) in a Divalent Cation-independent Manner.”The Journal of Biological Chemistry,vol. 269, pp. 26006-26010 (1994).
Kramer, Randall H. and Marks, Nancy, “Identification of Integrin Collagen Receptors on Human Melanoma Cells.”The Journal of Biological Chemistry,vol. 264, No. 8, pp. 4684-4688 (1988).
Moser, et al., “Evidence for Preferential Adhesion of Ovarian Epithelial Carcinoma Cells to Type I Collagen Mediated by the α2β1 Integrin.”Int. J. Cancer,vol. 67, pp. 695-701 (1996).
Natali, et al., “Clinical Significance of αvβ3Integrin and Intercellular Adhesion Molecule-1 Expression in Cutaneous Malignant Melanoma Lesions.”Cancer Research,vol. 57, pp. 1554-1560 (1997).
Nemunaitis, John, “Oncolytic viruses.”Investigational New Drugs,vol. 17, pp. 375-386 (1999).
Pietiäinen, Vilja, “Effects of echovirus 1 Infection on Cellular Gene Expression.”Virology,vol. 276, pp. 243-250 (2000).
Pevear, et al., “Activity of Pleconaril against Enteroviruses.”Antimicrobiol Agents and Chemotherapy,vol. 43, No. 9, pp. 2109-2115 (1999).
Ramos, et al., “Analysis of Integrin Receptors for Laminin and Type IV Collagen on Metastatic B16 Melanoma Cells.”Cancer Research,vol. 50, pp. 728-734 (1990).
Randazzo, et al., “Treatment of Experimental Intracranial Murine Melanoma with a Neuroattenuated Herpes Simplex Virus 1 Mutant.”Virology,vol. 211, pp. 94-101 (1995).
Rossman, et al., “Cell Recognition and Entry by Rhino- and Enteroviruses.”Virology,vol. 269, pp. 239-247 (2000).
Satyamoorthy, et al., “Adenovirus Infection Enhances Killing of Melanoma Cells by a Mitotoxin.”,Cancer Research,vol. 57, pp. 1873-1876 (1997).
Shafren, et al., “Coxsackievirus A21 Binds to Decay-Accelerating Factor but Requires Intercellular Adhesion Molecule 1 for Cell Entry.”Journal of Virology,vol. 71, No. 6, pp. 4736-4743 (1997).
Strong, et al., “The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus,”The EMBO Journal,vol. 17, No. 12, pp. 3351-3362 (1998).
Tsao, et al., “Characterization of Human Ovarian Surface Epithelial Cells Immortalized by Human Papilloma Viral Oncogenes (HPV-E6E7 ORFs).”Experimental Cell Research,vol. 218, pp. 499-507 (1995).
Xiao, et al., “Interaction of Coxsackievirus A21 with Its Cellular Receptor, ICAM-1.”Journal of Virology,vol. 75, No. 5, pp. 2444-2451 (2001).
Xing, Li, “Non-enveloped Virus Infection Probed with Host Cellular Molecules: A Structural Study.” Centre for Biotechnology, Department of Biosciences at Novum, Karolinska Institutet, Sweden: Stockholm 2002.
Anastassiou, G. et al. “Expression of VLA-2, VLA-3 and avintegrin receptors in ureal melanoma: association with microvascular architecture of the tumour and prognostic value”.Br. J. Ophthalmol.2000; 84:899-902.
Casasnovas, J.M. and Springer, T.A. “Pathway of Rhinovirus disruption by soluble intercellular adhesion molecule 1 (ICAM-1): an intermediate in which ICAM-I
Campell Bruce
DLA Piper (LLP) US
Li Bao Qun
Viralytics Limited
LandOfFree
Method of treating a malignancy in a subject via direct... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating a malignancy in a subject via direct..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating a malignancy in a subject via direct... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4086385